Endovascular Stenting in Superior Vena Cava Syndrome: A Systematic Review and Meta-analysis.
Endovascular stenting
Meta-analysis
Superior vena cava syndrome
Systematic review
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
20
06
2021
accepted:
15
05
2022
pubmed:
13
7
2022
medline:
14
9
2022
entrez:
12
7
2022
Statut:
ppublish
Résumé
Endovascular stenting has been used to manage superior vena cava syndrome for several decades and has become standard firstline practice. This study aims to investigate the outcomes of endovascular stenting in the management of superior vena cava syndrome (SVCS). MEDLINE, EMBASE and PUBMED online databases were searched, with studies involving more than ten adult patients included. Studies identified spanned 27 years, from 1993 to 2020. Meta-analyses were performed based on Clopper-Pearson estimation. Fifty-four studies were identified, for a total of 2249 patients, of which 2015 had malignant SVCS and 222 benign SVCS. Pooled technical success and clinical success rates were 96.8% (95% CI 96.0-97.5%) and 92.8% (95% CI 91.7-93.8%). Technical success and clinical success rates for studies investigating benign SVCS alone were identical at 88.8% (95% CI 83.0-93.1%). Pooled patency remained above 90% for the first year. Average complication and re-intervention rates were 5.78% (SD = 9.3182) and 9.11% (SD = 11.190). This review confirms the effectiveness of endovascular stenting in managing SVCS. Further directions of research may include specific outcomes of endovascular stenting in benign SVCS, and the impact of procedural characteristics, such as the use of anticoagulation and type of stent used, on outcomes. Level III, systematic review of retrospective cohort studies.
Identifiants
pubmed: 35821122
doi: 10.1007/s00270-022-03178-z
pii: 10.1007/s00270-022-03178-z
pmc: PMC9458578
doi:
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1236-1254Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
Friedman T, Quencer K, Kishore S, Winokur R, Madoff D. Malignant venous obstruction: superior vena cava syndrome and beyond. Semin Interv Radiol. 2017;34(04):398–408. https://doi.org/10.1055/s-0037-1608863 .
doi: 10.1055/s-0037-1608863
Cheng S. Superior vena cava syndrome. Cardiol Rev. 2009;17(1):16–23. https://doi.org/10.1097/crd.0b013e318188033c .
doi: 10.1097/crd.0b013e318188033c
pubmed: 19092366
Wilson L, Detterbeck F, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007;356(18):1862–9. https://doi.org/10.1056/nejmcp067190 .
doi: 10.1056/nejmcp067190
pubmed: 17476012
Azizi A, Shafi I, Shah N, Rosenfield K, Schainfeld R, Sista A, Bashir R. Superior vena cava syndrome. JACC Cardiovasc Interv. 2020;13(24):2896–910. https://doi.org/10.1016/j.jcin.2020.08.038 .
doi: 10.1016/j.jcin.2020.08.038
pubmed: 33357528
Rice T, Rodriguez R, Light R. The superior vena cava syndrome. Medicine. 2006;85(1):37–42. https://doi.org/10.1097/01.md.0000198474.99876.f0 .
doi: 10.1097/01.md.0000198474.99876.f0
pubmed: 16523051
Deshwal H, Ghosh S, Magruder K, Bartholomew J, Montgomery J, Mehta A. A review of endovascular stenting for superior vena cava syndrome in fibrosing mediastinitis. Vasc Med. 2019;25(2):174–83. https://doi.org/10.1177/1358863x19884130 .
doi: 10.1177/1358863x19884130
pubmed: 31804157
Sfyroeras G, Antonopoulos C, Mantas G, Moulakakis K, Kakisis J, Brountzos E, et al. A review of open and endovascular treatment of superior vena cava syndrome of benign aetiology. Eur J Vasc Endovasc Surg. 2017;53(2):238–54. https://doi.org/10.1016/j.ejvs.2016.11.013 .
doi: 10.1016/j.ejvs.2016.11.013
pubmed: 28007450
Chee C, Bjarnason H, Prasad A. Superior vena cava syndrome: an increasingly frequent complication of cardiac procedures. Nat Clin Pract Cardiovasc Med. 2007;4(4):226–30. https://doi.org/10.1038/ncpcardio0850 .
doi: 10.1038/ncpcardio0850
pubmed: 17380168
Butty S, Johnson M, Stevens D. Superior vena cava rupture and cardiac tamponade complicating the endovascular treatment of malignant superior vena cava syndrome: a case report and literature review. Semin Interv Radiol. 2015;32(04):439–44. https://doi.org/10.1055/s-0035-1564795 .
doi: 10.1055/s-0035-1564795
Rizvi A, Kalra M, Bjarnason H, Bower T, Schleck C, Gloviczki P. Benign superior vena cava syndrome: stenting is now the first line of treatment. J Vasc Surg. 2008;47(2):372–80. https://doi.org/10.1016/j.jvs.2007.09.071 .
doi: 10.1016/j.jvs.2007.09.071
pubmed: 18241760
Rachapalli V, Boucher L. Superior vena cava syndrome: role of the interventionalist. Can Assoc Radiol J. 2014;65(2):168–76. https://doi.org/10.1016/j.carj.2012.09.003 .
doi: 10.1016/j.carj.2012.09.003
pubmed: 23415716
Nicholson A, Ettles D, Arnold A, Greenstone M, Dyet J. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol. 1997;8(5):781–8. https://doi.org/10.1016/s1051-0443(97)70660-2 .
doi: 10.1016/s1051-0443(97)70660-2
pubmed: 9314368
McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319:388–96.
doi: 10.1001/jama.2017.19163
Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (2021). Retrieved 17 May 2021
Gaines P, Belli A, Anderson P, McBride K, Hemingway A. Superior vena caval obstruction managed by the gianturco Z stent. Clin Radiol. 1994;49(3):202–8. https://doi.org/10.1016/s0009-9260(05)81778-7 .
doi: 10.1016/s0009-9260(05)81778-7
pubmed: 8143414
Niu S, Xu Y, Cheng L, Cao C. Stent insertion for malignant superior vena cava syndrome: effectiveness and long-term outcome. Radiol Med (Torino). 2017;122(8):633–8. https://doi.org/10.1007/s11547-017-0767-1 .
doi: 10.1007/s11547-017-0767-1
Wei S, Liu J, Li X, Song Z, Dong M, Zhao H, et al. A retrospective stenting study on superior vena cava syndrome caused by lung cancer. Thorac Cancer. 2020;11(7):1835–9. https://doi.org/10.1111/1759-7714.13461 .
doi: 10.1111/1759-7714.13461
pubmed: 32438532
pmcid: 7327698
Oudkerk M, Kuijpers T, Schmitz P, Loosveld O, de Wit R. Self-expanding metal stents for palliative treatment of superior vena caval syndrome. Cardiovasc Interv Radiol. 1996;19(3):146–51. https://doi.org/10.1007/s002709900032 .
doi: 10.1007/s002709900032
Lanciego C, Chacón J, Julián A, Andrade J, López L, Martinez B, et al. Stenting as first option for endovascular treatment of malignant superior vena cava syndrome. Am J Roentgenol. 2001;177(3):585–93. https://doi.org/10.2214/ajr.177.3.1770585 .
doi: 10.2214/ajr.177.3.1770585
Bierdrager E, Lampmann LE, Lohle PN, Schoemaker CM, Schijen JH, Palmen FM, van der Heul C. Endovascular stenting in neoplastic superior vena cava syndrome prior to chemotherapy or radiotherapy. Neth J Med. 2005;63(1):20–3.
pubmed: 15719848
Lanciego C, Pangua C, Chacón J, Velasco J, Boy R, Viana A, et al. Endovascular stenting as the first step in the overall management of malignant superior vena cava syndrome. Am J Roentgenol. 2009;193(2):549–58. https://doi.org/10.2214/ajr.08.1904 .
doi: 10.2214/ajr.08.1904
Majumdar S, Shoela R, Kim D, Ramaswamy R, Mani N, Salter A, Akinwande O. Endovascular management of SVC syndrome due to fibrosing mediastinitis—a feasibility and safety analysis. Vasc Endovasc Surg. 2018;52(3):202–6. https://doi.org/10.1177/1538574418757401 .
doi: 10.1177/1538574418757401
Maleux G, Gillardin P, Fieuws S, Heye S, Vaninbroukx J, Nackaerts K. Large-bore nitinol stents for malignant superior vena cava syndrome: factors influencing outcome. Am J Roentgenol. 2013;201(3):667–74. https://doi.org/10.2214/ajr.12.9582 .
doi: 10.2214/ajr.12.9582
Cho Y, Gwon D, Ko G, Ko H, Kim J, Shin J, et al. Covered stent placement for the treatment of malignant superior vena cava syndrome: is unilateral covered stenting safe and effective? Korean J Radiol. 2014;15(1):87. https://doi.org/10.3348/kjr.2014.15.1.87 .
doi: 10.3348/kjr.2014.15.1.87
pubmed: 24497797
pmcid: 3909867
Gwon D, Ko G, Kim J, Shin J, Yoon H, Sung K. Malignant superior vena cava syndrome: a comparative cohort study of treatment with covered stents versus uncovered stents. Radiology. 2013;266(3):979–87. https://doi.org/10.1148/radiol.12120517 .
doi: 10.1148/radiol.12120517
pubmed: 23249571
Haddad M, Simmons B, McPhail I, Kalra M, Neisen M, Johnson M, et al. Comparison of covered versus uncovered stents for benign superior vena cava (SVC) obstruction. Cardiovasc Interv Radiol. 2018;41(5):712–7. https://doi.org/10.1007/s00270-018-1906-3 .
doi: 10.1007/s00270-018-1906-3
Wang Z, Li C, Li J, Wu W, Li Y, Shi J. Covered versus uncovered stent insertion for malignant superior vena cava obstruction. Minim Invasive Ther Allied Technol. 2019;29(6):353–8. https://doi.org/10.1080/13645706.2019.1653925 .
doi: 10.1080/13645706.2019.1653925
pubmed: 31430213
Dyet J, Nicholson A, Cook A. The use of the wallstent endovascular prosthesis in the treatment of malignant obstruction of the superior vena cava. Clin Radiol. 1993;48(6):381–5. https://doi.org/10.1016/s0009-9260(05)81105-5 .
doi: 10.1016/s0009-9260(05)81105-5
pubmed: 8293642
Sasano S, Onuki T, Mae M, Oyama K, Sakuraba M, Nitta S. Wallstent endovascular prosthesis for the treatment of superior vena cava syndrome. Jpn J Thorac Cardiovasc Surg. 2001;49(3):165–70. https://doi.org/10.1007/bf02913595 .
doi: 10.1007/bf02913595
pubmed: 11305056
Urruticoechea A. Treatment of malignant superior vena cava syndrome by endovascular stent insertion experience on 52 patients with lung cancer. Lung Cancer. 2004;43(2):209–14. https://doi.org/10.1016/s0169-5002(03)00361-1 .
doi: 10.1016/s0169-5002(03)00361-1
pubmed: 14739042
Nagata T, Makutani S, Uchida H, Kichikawa K, Maeda M, Yoshioka T, et al. Follow-up results of 71 patients undergoing metallic stent placement for the treatment of a malignant obstruction of the superior vena cava. Cardiovasc Interv Radiol. 2007;30(5):959–67. https://doi.org/10.1007/s00270-007-9088-4 .
doi: 10.1007/s00270-007-9088-4
Gross C, Krämer J, Waigand J, Uhlich F, Schröder G, Thalhammer C, et al. Stent implantation in patients with superior vena cava syndrome. Am J Roentgenol. 1997;169(2):429–32. https://doi.org/10.2214/ajr.169.2.9242747 .
doi: 10.2214/ajr.169.2.9242747
Qanadli S, El Hajjam M, Mignon F, de Kerviler E, Rocha P, Barré O, et al. Subacute and chronic benign superior vena cava obstructions: endovascular treatment with self-expanding metallic stents. Am J Roentgenol. 1999;173(1):159–64. https://doi.org/10.2214/ajr.173.1.10397119 .
doi: 10.2214/ajr.173.1.10397119
Cho T, Janho K, Mohan I. The role of stenting the superior vena cava syndrome in patients with malignant disease. Angiology. 2010;62(3):248–52. https://doi.org/10.1177/0003319710382772 .
doi: 10.1177/0003319710382772
pubmed: 20834024
Crowe M, Davies C, Gaines P. Percutaneous management of superior vena cava occlusions. Cardiovasc Interv Radiol. 1995;18(6):367–72. https://doi.org/10.1007/bf00338303 .
doi: 10.1007/bf00338303
Tanigawa N, Sawada S, Mishima K, Okuda Y, Mizukawa K, Ohmura N, et al. Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Acta Radiol. 1998;39(6):669–74. https://doi.org/10.3109/02841859809175494 .
doi: 10.3109/02841859809175494
pubmed: 9817039
Thony F, Moro D, Witmeyer P, Angiolini S, Brambilla C, Coulomb M, Ferretti G. Endovascular treatment of superior vena cava obstruction in patients with malignancies. Eur Radiol. 1999;9(5):965–71. https://doi.org/10.1007/s003300050777 .
doi: 10.1007/s003300050777
pubmed: 10370001
Smayra T, Otal P, Chabbert V, Chemla P, Romero M, Joffre F, Rousseau H. Long-term results of endovascular stent placement in the superior caval venous system. Cardiovasc Interv Radiol. 2001;24(6):388–94. https://doi.org/10.1007/s00270-001-0055-1 .
doi: 10.1007/s00270-001-0055-1
Fagedet D, Thony F, Timsit J, Rodiere M, Monnin-Bares V, Ferretti G, et al. Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy. Cardiovasc Interv Radiol. 2011;36(1):140–9. https://doi.org/10.1007/s00270-011-0310-z .
doi: 10.1007/s00270-011-0310-z
Sobrinho G, Aguiar P. Stent placement for the treatment of malignant superior vena cava syndrome—a single-center series of 56 patients. Arch Bronconeumol (Engl Ed). 2014;50(4):135–40. https://doi.org/10.1016/j.arbr.2014.03.001 .
doi: 10.1016/j.arbr.2014.03.001
Leung S, Sung T, Wan A, Leung K, Kan W. Endovascular stenting in the management of malignant superior vena cava obstruction: comparing safety, effectiveness, and outcomes between primary stenting and salvage stenting. Hong Kong Med J. 2015. https://doi.org/10.12809/hkmj144363 .
doi: 10.12809/hkmj144363
pubmed: 26908271
Ren J, Cao C, Fu Y, Du H. Double stent insertion for combined malignant airway and superior vena cava obstruction. Medicine. 2019;98(21):e15777. https://doi.org/10.1097/md.0000000000015777 .
doi: 10.1097/md.0000000000015777
pubmed: 31124968
pmcid: 6571431
Duvnjak S, Andersen P. Palliative treatment of superior vena cava syndrome with nitinol stents. Int J Angiol. 2014;23(04):255–62. https://doi.org/10.1055/s-0034-1383432 .
doi: 10.1055/s-0034-1383432
pubmed: 25484557
pmcid: 4244246
Andersen P, Midtgaard A, Brenoe A, Elle B, Duvnjak S. A new nitinol stent for use in superior vena cava syndrome. Initial clinical experience. J Cardiovasc Surg. 2015;56(6):877–81.
Sacks D, McClenny T, Cardella J, Lewis C. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14(9):S199–202. https://doi.org/10.1097/01.rvi.0000094584.83406.3e .
doi: 10.1097/01.rvi.0000094584.83406.3e
pubmed: 14514818
Anton S, Oechtering T, Stahlberg E, Jacob F, Kleemann M, Barkhausen J, Goltz J. Endovascular stent-based revascularization of malignant superior vena cava syndrome with concomitant implantation of a port device using a dual venous approach. Support Care Cancer. 2017;26(6):1881–8. https://doi.org/10.1007/s00520-017-3997-9 .
doi: 10.1007/s00520-017-3997-9
pubmed: 29274029
Mokry T, Bellemann N, Sommer C, Heussel C, Bozorgmehr F, Gnutzmann D, et al. Retrospective study in 23 patients of the self-expanding sinus-XL stent for treatment of malignant superior vena cava obstruction caused by non-small cell lung cancer. J Vasc Interv Radiol. 2015;26(3):357–65. https://doi.org/10.1016/j.jvir.2014.11.019 .
doi: 10.1016/j.jvir.2014.11.019
pubmed: 25638748
Kishi K, Sonomura T, Mitsuzane K, Nishida N, Yang R, Sato M, et al. Self-expandable metallic stent therapy for superior vena cava syndrome: clinical observations. Radiology. 1993;189(2):531–5. https://doi.org/10.1148/radiology.189.2.8210386 .
doi: 10.1148/radiology.189.2.8210386
pubmed: 8210386
Dinkel H, Mettke B, Schmid F, Baumgartner I, Triller J, Do D. Endovascular treatment of malignant superior vena cava syndrome: is bilateral wallstent placement superior to unilateral placement? J Endovasc Ther. 2003;10(4):788–97. https://doi.org/10.1177/152660280301000416 .
doi: 10.1177/152660280301000416
pubmed: 14533962
Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the CIRSE classification system. Cardiovasc Intervent Radiol. 2017;40(8):1141–6. https://doi.org/10.1007/s00270-017-1703-4 .
doi: 10.1007/s00270-017-1703-4
pubmed: 28584945
Stock K, Jacob A, Proske M, Bolliger C, Rochlitz C, Steinbrich W. Treatment of malignant obstruction of the superior vena cava with the self-expanding Wallstent. Thorax. 1995;50(11):1151–6. https://doi.org/10.1136/thx.50.11.1151 .
doi: 10.1136/thx.50.11.1151
pubmed: 8553270
pmcid: 475086
Barshes N, Annambhotla S, El Sayed H, Huynh T, Kougias P, Dardik A, Lin P. Percutaneous stenting of superior vena cava syndrome: treatment outcome in patients with benign and malignant etiology. Vascular. 2007;15(5):314–21. https://doi.org/10.2310/6670.2007.00067 .
doi: 10.2310/6670.2007.00067
pubmed: 17976332
de Gregorio Ariza M, Gamboa P, Gimeno M, Alfonso E, Mainar A, Medrano J, et al. Percutaneous treatment of superior vena cava syndrome using metallic stents. Eur Radiol. 2003;13(4):853–62. https://doi.org/10.1007/s00330-002-1489-9 .
doi: 10.1007/s00330-002-1489-9
pubmed: 12664126
Mónaco R. Use of self-expanding vascular endoprostheses in superior vena cava syndrome. Eur J Cardiothorac Surg. 2003;24(2):208–11. https://doi.org/10.1016/s1010-7940(03)00293-8 .
doi: 10.1016/s1010-7940(03)00293-8
Ratzon R, Tamir S, Friehmann T, Livneh N, Dudnik E, Rozental A, et al. Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome. J Thromb Thrombol. 2018;47(1):121–8. https://doi.org/10.1007/s11239-018-1747-6 .
doi: 10.1007/s11239-018-1747-6
Haddad M, Thompson S, McPhail I, Bendel E, Kalra M, Stockland A, et al. Is long-term anticoagulation required after stent placement for benign superior vena cava syndrome? J Vasc Interv Radiol. 2018;29(12):1741–7. https://doi.org/10.1016/j.jvir.2018.07.020 .
doi: 10.1016/j.jvir.2018.07.020
pubmed: 30396845
Hennequin L, Fade O, Fays J, Bic J, Jaafar S, Bertal A, et al. Superior vena cava stent placement: results with the wallstent endoprosthesis. Radiology. 1995;196(2):353–61. https://doi.org/10.1148/radiology.196.2.7617844 .
doi: 10.1148/radiology.196.2.7617844
pubmed: 7617844
Shah R, Sabanathan S, Lowe R, Mearns A. Stenting in malignant obstruction of superior vena cava. J Thorac Cardiovasc Surg. 1996;112(2):335–40. https://doi.org/10.1016/s0022-5223(96)70259-3 .
doi: 10.1016/s0022-5223(96)70259-3
pubmed: 8751500
Marcy P, Magné N, Bentolila F, Drouillard J, Bruneton J, Descamps B. Superior vena cava obstruction: is stenting necessary? Support Care Cancer. 2001;9(2):103–7. https://doi.org/10.1007/s005200000173 .
doi: 10.1007/s005200000173
pubmed: 11305067
Miller J, McBride K, Little F, Price A. Malignant superior vena cava obstruction: stent placement via the subclavian route. Cardiovasc Interv Radiol. 2000;23(2):155–8. https://doi.org/10.1007/s002709910033 .
doi: 10.1007/s002709910033
Chatziioannou A, Alexopoulos T, Mourikis D, Dardoufas K, Katsenis K, Lazarou S, et al. Stent therapy for malignant superior vena cava syndrome. Eur J Radiol. 2003;47(3):247–50. https://doi.org/10.1016/s0720-048x(02)00207-3 .
doi: 10.1016/s0720-048x(02)00207-3
pubmed: 12927670
Courtheoux P, Alkofer B, Al Refaï M, Gervais R, Le Rochais J, Icard P. Stent placement in superior vena cava syndrome. Ann Thorac Surg. 2003;75(1):158–61. https://doi.org/10.1016/s0003-4975(02)04293-5 .
doi: 10.1016/s0003-4975(02)04293-5
pubmed: 12537210
Kim Y, Kim K, Ko Y, Park C, Lim S, Kim Y, et al. Endovascular stenting as a first choice for the palliation of superior vena cava syndrome. J Korean Med Sci. 2004;19(4):519. https://doi.org/10.3346/jkms.2004.19.4.519 .
doi: 10.3346/jkms.2004.19.4.519
pubmed: 15308841
pmcid: 2816884
Sheikh M, Fernandez B, Gray B, Graham L, Carman T. Endovascular stenting of nonmalignant superior vena cava syndrome. Catheter Cardiovasc Interv. 2005;65(3):405–11. https://doi.org/10.1002/ccd.20458 .
doi: 10.1002/ccd.20458
pubmed: 15945106
Breault S, Doenz F, Jouannic A, Qanadli S. Percutaneous endovascular management of chronic superior vena cava syndrome of benign causes: long-term follow-up. Eur Radiol. 2016;27(1):97–104. https://doi.org/10.1007/s00330-016-4354-y .
doi: 10.1007/s00330-016-4354-y
pubmed: 27085696
Miazga M, Jargiełło T, Drelich-Zbroja A, Karska K, Pyra K, Sojka M, et al. Endovascular treatment for superior vena cava obstruction. Postępy Nauk Medycznych. 2015;28(2):124–8. https://doi.org/10.5604/08606196.1150855 .
doi: 10.5604/08606196.1150855
Calsina Juscafresa L, Gil Bazo I, Grochowicz L, Páramo Alfaro M, López-Picazo González J, Moreno Jiménez M, Bilbao Jaureguizar J. Endovascular treatment of malignant superior vena cava syndrome secondary to lung cancer. Hosp Pract. 2017;45(3):70–5. https://doi.org/10.1080/21548331.2017.1342507 .
doi: 10.1080/21548331.2017.1342507
Kuo T, Chen P, Shih C, Chen I. Endovascular stenting for end-stage lung cancer patients with superior vena cava syndrome post first-line treatments—a single-center experience and literature review. J Chin Med Assoc. 2017;80(8):482–6. https://doi.org/10.1016/j.jcma.2017.04.005 .
doi: 10.1016/j.jcma.2017.04.005
pubmed: 28501315
Büstgens F, Loose R, Ficker J, Wucherer M, Uder M, Adamus R. Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2017;189(05):423–430. https://doi.org/10.1055/s-0042-122147 .
doi: 10.1055/s-0042-122147
Wilson LD, Detterbeck FC, Yahalom J. Superior Vena Cava Syndrome with Malignant Causes. N Engl J Med. 2007;356(18):1862–1869. https://doi.org/10.1056/NEJMcp067190 .
doi: 10.1056/NEJMcp067190
pubmed: 17476012
Massara M, De Caridi G, Alberti A, Volpe P, Spinelli F. Symptomatic superior vena cava syndrome in hemodialysis patients: mid-term results of primary stenting. Semin Vasc Surg. 2016;29(4):186–191. https://doi.org/10.1053/j.semvascsurg.2017.05.001 .
doi: 10.1053/j.semvascsurg.2017.05.001
pubmed: 28779785
Karakhanian WK, Karakhanian WZ, Belczak SQ. Superior vena cava syndrome: endovascular management. J Vasc Bras. 2019;18:e20180062. https://doi.org/10.1590/1677-5449.180062 .
doi: 10.1590/1677-5449.180062
pubmed: 31616492
pmcid: 6774659